1. Oral Semaglutide: Dosage in Special Situations

   • Sanjay Kalra
   • Nitin Kapoor

   Commentary Open access 07 May 2022 Pages: 1133 - 1137

2. Measuring the Impact of Flash Glucose Monitoring in a Pediatric Population in Saudi Arabia: A Retrospective Cohort Study

   • Mohammed Y. Alharbi
   • Abdulhameed Albunyan
   • Husam Al Ahmadi

   Original Research Open access 20 April 2022 Pages: 1139 - 1146

   

3. Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain

   • Miriam Rubio de Santos
   • Esther Artime
   • Alberto Fernández

   Original Research Open access 21 April 2022 Pages: 1147 - 1160

   

4. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus^®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial

   • Xiang Yan
   • Chen Feng
   • Zhiguang Zhou

   Original Research Open access 26 April 2022 Pages: 1161 - 1174

   

5. Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies

   • Mark Evans
   • Zoë Welsh
   • Alexander Seibold

   Original Research Open access 27 April 2022 Pages: 1175 - 1185

   

6. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

   • Gagik R. Galstyan
   • Amir Tirosh
   • Niaz Khan

   Original Research Open access 09 May 2022 Pages: 1187 - 1202

   

7. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK

   • Rory J. McCrimmon
   • Karen Palmer
   • Amar Puttanna

   Original Research Open access 11 May 2022 Pages: 1203 - 1214

   

8. Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers

   • Yvonne Schnaars
   • Sumedh Gaikwad
   • Vamshi Ramana Prathap

   Original Research Open access 11 May 2022 Pages: 1215 - 1229

   

9. Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)

   • Lixin Guo
   • Li Li
   • Yuchen Ding

   Original Research Open access 18 May 2022 Pages: 1231 - 1244

   

10. Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying

    • Chinmay S. Marathe
    • Hung Pham
    • Karen L. Jones

    Brief Report Open access 22 April 2022 Pages: 1245 - 1249

    

11. Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria

    • Chiara Di Loreto
    • Viviana Minarelli
    • Paola Del Sindaco

    Correction Open access 23 April 2022 Pages: 1251 - 1251